An open-label, Phase 1 study to evaluate the drug-drug interaction between ulonivirine and the combined oral contraceptive levonorgestrel/ethinyl estradiol in female participants without HIV
ABSTRACT Ulonivirine is a non-nucleoside reverse transcriptase inhibitor in development as an oral, once-weekly treatment for HIV-1 in combination with investigational islatravir. The effect of ulonivirine on the pharmacokinetics of an oral contraceptive, levonorgestrel (LNG)/ethinyl estradiol (EE) was evaluated in fem...